Antihyperalgesic activity of a novel synthesized analogue of lidocaine in diabetic rats 

Simple item page
dc.contributor.affiliationInstituto Politecnico Nacional, Sección de Estudios Posgrado e Investigación, Plan San Luis y Diaz Miron S-N, Mexico City 11340, DF, Mexico.es_ES
dc.contributor.emailmyrnadeciga@hotmail.com es_ES
dc.creatorGarcia-Hernandez, Liliana
dc.creatorNavarrete-Vazquez, Gabriel
dc.creatorGonzalez-Trujano, Maria Eva
dc.creatorJavier Lopez-Munoz, Francisco
dc.creatorDeciga-Campos, Myrna
dc.creator.identificadorhttp://orcid.org/0000-0001-5344-4762>Navarrete Vazquez, Gabrieles_ES
dc.creator.identificadorGOTE681027MMCNRV09>Gonzalez Trujano, Maria Evaes_ES
dc.creator.identificadorhttp://orcid.org/0000-0002-0700-8385>Javier López Muñoz, Franciscoes_ES
dc.creator.identificadorDECM730906MDFCMY06>Deciga Campos, Myrnaes_ES
dc.date.accessioned2017-06-29T03:41:38Z
dc.date.accessioned2026-03-27T14:33:35Z
dc.date.available2017-06-29T03:41:38Z
dc.date.issued2013es_ES
dc.date.published2013es_ES
dc.description.abstractotrodiomaObjectives The purpose of this study was to assess the antinociceptive and antihyperalgesic effects of a lidocaine analogue N-(2,6-dichlorophenyl)-2-(4-methyl-1-piperidinyl)acetamide (LIA). Methods The structure of LIA was established by elemental analysis and compatible IR, 1H NMR, 13C NMR, and spectral data. Nociceptive and hyperalgesic activity were evaluated in normoglycaemic and streptozocin-induced diabetic rats using the formalin test. Formalin-evoked flinching, an indication of nociception and hyperalgesia, was increased in diabetic rats (using 0.5% formalin) compared with nondiabetic rats (using 1% formalin). Key findings Local administration of LIA into the dorsal surface of the right hind paw (0.185.6mg per paw) significantly reduced the formalin-induced nociceptive and hyperalgesic behaviour of nondiabetic and diabetic rat. The antinociceptive effect of LIA was higher than that of lidocaine injection, furthermore this effect was higher than that of gabapentin. Conclusions LIA may have potential as a treatment for diabetic hyperalgesia. Further investigations of the antinociceptive mechanisms and the safety of this new compound are necessary.es_ES
dc.description.monthMayes_ES
dc.identifier2544es_ES
dc.identifier.citationAlberto Darío Ramírez Gonzálezes_ES
dc.identifier.doi10.1111/jphp.12025 es_ES
dc.identifier.eissn2042-7158es_ES
dc.identifier.issn0022-3573es_ES
dc.identifier.numero5es_ES
dc.identifier.organizacionInstituto Nacional de Psiquiatría Ramón de la Fuente Muñizes_ES
dc.identifier.paginacion689-696es_ES
dc.identifier.placeHobokenes_ES
dc.identifier.urihttps://doi.org/10.1111/jphp.12025es_ES
dc.identifier.urihttps://repositorio.inprf.gob.mx/handle/123456789/4393
dc.identifier.volumen65es_ES
dc.language.isoenges_ES
dc.publisherWiley-Blackwell, 111 River ST, Hoboken 07030-5774, NJ USA es_ES
dc.relation65(5) 689-696p.es_ES
dc.relationversión del editores_ES
dc.relation.jnabreviadoJ PHARM PHARMACOLes_ES
dc.relation.journalThe Journal of pharmacy and pharmacologyes_ES
dc.rightsacceso cerradoes_ES
dc.subject.koAnalogue of lidocainees_ES
dc.subject.koDiabetic painful neuropathyes_ES
dc.subject.koHyperalgesiaes_ES
dc.subject.koNociceptiones_ES
dc.titleAntihyperalgesic activity of a novel synthesized analogue of lidocaine in diabetic rats es_ES
dc.typeartículoes_ES

Files

Collections

Artículos de revista